Ceribell, Inc. Cash Flow Statement
CBLL / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Ceribell, Inc. used $41M in operating cash flow and negative free cash flow of $42M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$53.4M | -$29.5M | -$29.5M |
| Depreciation & Amortization | $1.3M | $847.0K | $847.0K |
| Operating Cash Flow | -$40.8M | -$29.2M | -$29.2M |
| Capital Expenditures | $767.0K | $983.0K | $983.0K |
| Free Cash Flow | -$41.6M | -$30.1M | -$30.1M |
| FCF Margin | -46.7% | -66.6% | - |